New drug duo aims to shrink tumors before chemo in aggressive breast cancer
NCT ID NCT06353997
Summary
This study is testing whether a new two-drug immunotherapy combination can shrink tumors in patients with stage II or III triple-negative breast cancer before they start standard chemotherapy. The trial will enroll 12 patients who have not yet received any treatment for their cancer. Researchers will use ultrasound to measure if the tumor shrinks by at least 30% after two cycles of the experimental treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ellison Institute of Technology (EITM)
RECRUITINGLos Angeles, California, 90064, United States
Contact Phone: •••-•••-••••
-
Providence Portland Cancer Institute - Franz Clinic
RECRUITINGPortland, Oregon, 97213, United States
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact
Contact
Contact
-
Providence St. Vincent Medical Center
RECRUITINGPortland, Oregon, 97225, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Swedish Cancer Institute
NOT_YET_RECRUITINGSeattle, Washington, 98104, United States
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.